Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs: Dose-dependent pharmacokinetics

Drug Metabolism and Disposition

Volumn 25, Issue 3, 1997, Pages 355-361

  Prueksaritanont, Thomayant ^a   Gorham, Lynn M ^b   Naue, Jeanne A ^b   Hamill, Terrence G ^b   Askew, Ben C ^b   Vyas, Kamlesh P ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; DOG; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; AZEPINES; BLOOD PLATELETS; BLOOD PROTEINS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; INJECTIONS, INTRAVENOUS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; SULFONAMIDES; TRITIUM;

ANIMALIA; CANIS FAMILIARIS;

EID: 0030997245     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. D. R. Phillips, I. F. Charo, L. V. Panse, and L. A. Fitzgerald: The platelet membrane glycoprotein IIb-IIIa complex. Blood 71, 831-843 (1988).
2. W. H. Frishman, B. Burns, B. Atac, N. Alturk, B. Altajar, and K. Lerrick: Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am. Heart J. 130, 877-892 (1995).
3. E. J. Topol: Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am. Heart J. 130, 666-672 (1995).
4. EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N. Engl. J. Med. 330, 956-961 (1994).
5. J. Samanen, F. Ali, T. Romoff, R. Calvo, E. Sorenson, J. Vasko, B. Storer, D. Berry, D. Bennett, M. Strohsacker, D. Powers, J. Stadel, and A. Nichols: Development of a small RGD peptide fibrinogen receptor antagonist with potent anti-aggregatory activity in vitro. J. Med. Chem. 34, 3114-3125 (1991).
6. L. Alig, A. Edenhofer, P. Hadv́ary, M. Hürzeler, D. Knopp, M. Müller, B. Steiner, A. Trzeciak, and T. Weller: Low molecular weight, non-peptide fibrinogen receptor antagonists. J. Med. Chem. 35, 4393-4407 (1992).
7. G. D. Hartman, M. S. Egbertson, W. Halczenko, W. L. Laswell, M. E. Duggan, R. L. Smith, A. M. Naylor, P. D. Manno, R. J. Lynch, G. Zhang, C.T.-C. Chang, and R. J. Gould: Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640-4642 (1992).
8. J. A. Zablocki, F. S. Tjoeng, P. R. Bovy, M. Miyano, R. B. Garland, K. Williams, L. Schretzman, M. E. Zupec, J. G. Rico, R. J. Lindmark, M. V. Toth, D. E. McMackins, S. P. Adams, S. G. Panzer-Knodle, N. S. Nicholson, B. B. Taite, A. K. Salyers, L. W. King, J. G. Campion, and L. P. Feigen: A novel series of orally active antiplatelet agents. Bioorgan. Med. Chem. 3, 539-551 (1995).
9. R. A. Harrington, S. P. Schulman, N. S. Kleiman, A. M. Lincoff, P. J. Goldschmidt-Clermont, D. Joseph, K. N. Sigmon, J. Parker, K. Marchant, and M. M. Kitt: Profound sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation 90, 1-232 (1994).
10. P. Théroux, S. Kouz, M. L. Knudtson, C. Kells, J. Nasmith, L. Roy, S. Dalle Ave, B. Steiner, Z. Xiao, and H. J. Rapold: A randomized double-blind controlled trial with the non-peptide platelet GP IIb/IIIa antagonist Ro 44-9883 in unstable angina. Circulation 90, 1-242 (1994).
11. D. Kereiakes, N. Kleiman, J. Ambrose, M. Cohen, S. Rodriquez, T. Palabrica, H. C. Herrmann, J. Sutton, W. D. Weaver, D. McKee, and F. L. Sax: A dosing study in high-risk PTCA of MK-383, a platelet IIb/IIIa antagonist. Circulation 90, 1-21 (1994).
12. R. J. Anders, J. C. Alexander, G. L. Hantsbarger, D. M. Burns, S. D. Oliver, G. Cole, and D. J. Fitzgerald: Demonstration of potent inhibition of platelet aggregation with an orally active GP IIb/IIIa receptor antagonist. J. Am. Coll. Cardiol. 25, 117A (1995).
13. T. H. Müller, H. Weisenberger, R. Brickl, M. Kirchner, H. Narjes, F. Himmelsbach, B. Guth, and J. Krause: Pharmaco-dynamics and -kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in man. Thromb. Haemostas. 73, 1445 (1995).
14. B. C. Askew, C. J. McIntyre, C. A. Hunt, D. A. Claremon, D. J. Armstrong, J. J. Cook, J. J. Lynch, R. J. Gould, B. Bednar, R. A. Bednar, and C. T-C. Chang: Non-peptide fibrinogen receptor antagonists. Design and synthesis of an orally active antiplatelet agent. J. Med. Chem. in press.
15. R. A. Bednar, S. L. Gaul, J. J. Cook, B. C. Askew, J. J. Lynch, G. D. Hartman, R. J. Gould, and B. Bednar: Novel mechanism for long-acting GP IIb/IIIa antagonists. Circulation 94, 1-98 (1996).
16. J. J. Cook, J. A. Glass, G. R. Sitko, M. A. Holahan, R. F. Stupienski, A. A. Wallace, G. L. Stump, T. Kothstein, D. Jones, J. R. Gehret, B. C. Askew, C. J. McIntyre, C. A. Hunt, D. J. Armstrong, D. A. Claremon, P. S. Anderson, J. J. Baldwin, G. D. Hartman, R. J. Gould, and J. J. Lynch: Non-peptide glycoprotein IIb/IIIa inhibitors. 14. Oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury. Circulation, in press.
17. L. Z. Benet and R. L. Galeazzi: Noncompartment determination of the steady-state volume of distribution. J. Pharm. Sci. 68, 1071-1072 (1979).
18. T. Prueksaritanont, M. Stranieri, G. Sitko, L. Hands, J. D. Ellis, M. Holahan, and J. J. Cook: Effects of pentobarbital on pharmacokinetics and pharmacodynamics of L-734,217, a potent fibrinogen receptor antagonist in dogs. Biopharm. Drug Disp. in press.
19. J. S. Barrett, R. J. Gould, J. D. Ellis, M. A. Holahan, M. T. Stranieri, J. J. Lynch, G. D. Hartman, N. Ihle, M. Duggan, O. A. Moreno, and A. D. Theoharides: Pharmacokinetics and pharmacodynamics of L-703,104, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. Pharm. Res. 11, 426-431 (1994).
20. S. Vickers, S. K. Balani, C. A. Duncan, J. D. Ellis, L. Gorham, T. Prueksaritanont, D. E. Slaughter, A. Theoharides, and K. P. Vyas: In vitro and in vivo metabolism studies on tirofiban in rats, dogs and humans. ISSX Proc. 10, 215 (1996).
21. C. D. Klaassen and J. B. Watkins III: Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol. Rev. 36, 1-67 (1984).
22. G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance. Clin. Pharmacol. 18, 377-390 (1975).
23. K. Niiya, E. Hodson, R. Bader, V. Byers-Ward, J. A. Koziol, E. F. Plow, and Z. M. Ruggeri: Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 70, 475-483 (1987).
24. B. Davies and T. Morris: Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
25. M. Gibaldi and D. Perrier (eds.): "Pharmacokinetics," 2nd ed., pp. 199-219. Marcel Dekker, New York, 1982.
26. J. H. Lin, E. H. Ulm, and L. E. Los: Dose-dependent stereopharmacokinetics of 5,6-dihydro-4H-4(isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7,7-dioxide, a potent carbonic anhydrase inhibitor, in rats. Drug Metab. Disp. 19, 233-238 (1991).
27. J. H. Lin, I.-W. Chen and F. A. deLuna: Dose-dependent pharmacokinetics of MK-417, a carbonic anhydrase inhibitor, in experimental polycythemia and anemic rats. Pharm. Res. 8, 608-614 (1991).